STOCK TITAN

Director at Ardent Health (ARDT) granted 14,231 restricted stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Webb Robert Thomas reported acquisition or exercise transactions in this Form 4 filing.

Ardent Health, Inc. director Robert Thomas Webb reported an equity award of 14,231 shares of Common Stock, received as a grant on April 1, 2026 at no purchase price. These represent restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, Webb directly holds a total of 78,215 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider Webb Robert Thomas
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 14,231 $0.00 --
Holdings After Transaction: Common Stock — 78,215 shares (Direct)
Footnotes (1)
  1. [object Object]
Shares granted 14,231 shares of Common Stock Equity award on April 1, 2026
Grant price $0.0000 per share Reported transaction price per share
Total shares after transaction 78,215 shares Direct holdings following the grant
Vesting schedule Vest on first anniversary of April 1, 2026 Restricted stock units vesting condition
restricted stock units financial
"Represents restricted stock units that vest in full on the first anniversary"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest financial
"that vest in full on the first anniversary of April 1, 2026"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service financial
"subject to the Reporting Person's continued service with the Issuer"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Webb Robert Thomas

(Last)(First)(Middle)
340 SEVEN SPRINGS WAY, SUITE 100

(Street)
BRENTWOOD TENNESSEE 37027

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ardent Health, Inc. [ ARDT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026A14,231(1)A$078,215D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to the Reporting Person's continued service with the Issuer through the vesting date.
Remarks:
/s/ Stephen C. Petrovich, Attorney-in-Fact04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ARDT director Robert Thomas Webb report?

Robert Thomas Webb reported receiving an equity award of 14,231 shares of Ardent Health Common Stock. The transaction was coded as a grant or award, meaning the shares were acquired as compensation rather than purchased in the open market.

Was cash paid for the 14,231 Ardent Health (ARDT) shares granted?

No cash was paid for these 14,231 shares; the reported price per share was 0.0000. This indicates a compensatory grant of restricted stock units rather than an open-market purchase, aligning with common director and executive equity incentive practices.

How many Ardent Health (ARDT) shares does Robert Thomas Webb hold after this grant?

After the grant, Robert Thomas Webb directly holds 78,215 shares of Ardent Health Common Stock. This total includes the newly awarded 14,231 restricted stock units and reflects his direct ownership position immediately following the reported transaction.

When do Robert Thomas Webb’s 14,231 Ardent Health restricted stock units vest?

The 14,231 restricted stock units vest in full on the first anniversary of April 1, 2026. Vesting is conditioned on Webb’s continued service with Ardent Health through that vesting date, as specified in the transaction footnote.

Is the Ardent Health (ARDT) insider transaction a market buy or compensation grant?

The transaction is a compensation grant, not a market purchase. It is coded as a grant, award, or other acquisition, with a zero-dollar price per share, indicating restricted stock units granted as part of Webb’s role rather than shares bought on the open market.

What conditions apply to Robert Thomas Webb’s Ardent Health (ARDT) stock grant?

The restricted stock units are subject to a service-based condition. They will vest in full on the first anniversary of April 1, 2026 only if Robert Thomas Webb continues his service with Ardent Health through that vesting date, according to the disclosed footnote.